Tuesday, 18 Jun 2019

You are here

RheumNow Podcast – Rituximab Monitoring (5.31.19)

Dr. Jack Cush presents the news and best of rheumatology and medicine from the past week on RheumNow.com

  1. Korean National Health Insurance data compared the risk of CV events in 39,640 gout pts starting allopurinol or febuxostat. MACE incidence was 1.89 vs 1.84/100PY (HR 1.09; 0.90, 1.32) Thus, no significant difference in CV risk with these agents in Asians https://buff.ly/2EJobhj     
  2. Risk factors for gouty tophi that ulcerate include: glucocorticoid overuse, tophi duration, and the number of tophi. Based on a chinese study of 105 tophaceous patients of whom 33 developed ulcerations https://t.co/rzYTFCb5jk 
  3. 184 juvenile Fibromyalga pts randomized to PBO or duloxetine (30-->60mg/d) for 13wks. Those on duloxetine failed the primary endpoint - mean 24 hr change in Brief Pain Inventory (BPI), but more Cymbalta pts had 30% and 50% BPI reductions https://t.co/EuyCRqKzN7 
  4. Lyrica is FDA approved for FM, Neuopathy & adjunctive Rx for partial-onset seizures; but recently failed to meet primary endpoint in a phase III RCT to prevent primary gen tonic-clonic seizures.- but is continuing to develop it for pediatric epilepsy. https://t.co/T9T0Kv1wkP 
  5. Japanese study 198 systemic sclerosis pts finds that higher skin thickness scores (modified Rodnan Skin Scores; mRSS) associated with higher risk of interstitial lung disease (P < 0.05), restrictive LDz(P < 0.01), and diffusion impairment (P < 0.05) https://t.co/PY4n6N5Ub9   
  6. Metanalysis suggests leflunomide in psoriatic disease is better at treating arthritis (PsA PsARC 77%) than skin disease (psoriasis PASI50 48% & PASI75 25%). Adverse events in 38% and 15% drop out rate. https://t.co/BIPNtYE6Tr 
  7. Large UK study shows central adiposity (waist circumference) signify increases risk of psoriasis and rheumatoid arthritis; not PsA. a cross-sectional study of the UK Biobank https://t.co/eKDpUodSR1 
  8. Prospective study of 4796 pts in Osteoarthritis Initiative shows metformin use in obese pts (BMI >30) was Assoc with significantly less medial cartilage loss (0.71% vs. 1.57%/yr) & a trend towards fewer knee replacements over 6 yrs (OR 0.30, p = 0.11) https://t.co/LD0jFWtSLM     
  9. Biologic Retention in Ankylosing Spondylitis Patients    
  10. The Cost of Physician Burnout  
  11. Predictors of Serious Infections with Rituximab  

 

Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

EULAR 2019- Day 4 Report

Saturday June 15th was the last half-day at EULAR 2019 but was highlighted by the “late-breaking” (LB) presentations that were presented from the podium and by poster.

Below are the top “LB” presentations from EULAR this year:

Understanding Non-arthritic Rheumatic iRAEs

A better understanding of rheumatic immune-related adverse event phenotypes beyond inflammatory arthritis has been furthered by work from three abstracts presented at EULAR 2019 in Madrid.

Ultrasound Reveals Which Anti-CCP Positive Patients Progress to Arthritis 

Power Doppler signal on baseline ultrasound exam may well help stratify anti-CCP positive patients with musculoskeletal symptoms but no clinical synovitis, according to data from the Leeds Institute of Rheumatic and Musculoskeletal Medicine presented at EULAR 2019.

EULAR 2019 – Day 3 Report

The third day of EULAR 2019 started with novel biologics, the efficacy of secukinumab in axial psoriatic arthritis, neurologic events with TNF inhibitors from the DANBIO database (OP0261), and neuropathy in SLE (OP0252), but above all this was a big poster day. Here are selected highlights from day 3 EULAR in Madrid.

RheumNow Podcast – EULAR 2019 Streamin' - (6.14.19)

Dr. Jack Cush reports from Madrid on several novel presentations from EULAR 2019.

1. Genovese Vagal nerve stimulator in RA

2. Low dose steroids in Hand OA